Inventor · disambiguated record
Eric G. Marcusson
Also filed as: MARCUSSON ERIC · MARCUSSON ERIC G
29 granted patents·25 pending applications·600 citations·filing 1999–2023
97Inventor score
Files withISIS PHARMACEUTICALS INC15REGULUS THERAPEUTICS INC10MARCUSSON ERIC G4BENNETT C FRANK3JAAN BIOTHERAPEUTICS LLC3
Top patents by PatentIndex Score
54 records- 0199US7217572B2Modulation of HIF1α and HIF2α expressionISIS PHARMACEUTICALS INC·Filed 2003·Granted May 15, 2007·139 cites·18 claims
- 0298US8133876B2Oligomeric compounds and compositions for use in modulation of small non-coding RNAsBENNETT C FRANK·Filed 2008·Granted Mar 13, 2012·44 cites·17 claims
- 0396US6001992AAntisense modulation of novel anti-apoptotic bcl-2-related proteinsISIS PHARMACEUTICALS INC·Filed 1999·Granted Dec 14, 1999·230 cites·40 claims
- 0494US8211867B2Targeting microRNAs for the treatment of liver cancerBENNETT C FRANK·Filed 2008·Granted Jul 3, 2012·23 cites·27 claims
- 0593US9546368B2Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1 (MALAT-1) expressionIONIS PHARMACEUTICALS INC·Filed 2012·Granted Jan 17, 2017·16 cites·20 claims
- 0692US9267137B2MicroRNA compounds and methods for modulating miR-21 activityREGULUS THERAPEUTICS INC·Filed 2015·Granted Feb 23, 2016·8 cites·21 claims
- 0792US7759318B1Identification of novel pathways, genes and promoter motifs regulating adipogenesisISIS PHARMACEUTICALS INC·Filed 2005·Granted Jul 20, 2010·23 cites·23 claims
- 0890US9688985B2MicroRNA compounds and methods for modulating miR-21 activityREGULUS THERAPEUTICS INC·Filed 2016·Granted Jun 27, 2017·6 cites·6 claims
- 0990US8969317B2MicroRNA compounds and methods for modulating miR-21 activityREGULUS THERAPEUTICS INC·Filed 2013·Granted Mar 3, 2015·9 cites·15 claims
- 1090US7425544B2Modulation of eIF4E expressionLILLY CO ELI·Filed 2004·Granted Sep 16, 2008·26 cites·16 claims
- 1188US8846631B2MicroRNA compositions and methodsMARCUSSON ERIC G·Filed 2011·Granted Sep 30, 2014·9 cites·15 claims
- 1286US11566243B2Compositions and methods for treatment of cardiac diseasesJAAN BIOTHERAPEUTICS LLC·Filed 2017·Granted Jan 31, 2023·4 cites·17 claims
- 1384US9506062B2Targeting microRNAs for the treatment of liver cancerREGULUS THERAPEUTICS INC·Filed 2015·Granted Nov 29, 2016·3 cites·24 claims
- 1484US8680067B2Targeting microRNAs for the treatment of liver cancerBENNETT C FRANK·Filed 2012·Granted Mar 25, 2014·5 cites·25 claims
- 1584US7601700B2Modulation of eIF4E expressionLILLY CO ELI·Filed 2008·Granted Oct 13, 2009·4 cites·16 claims
- 1683US9150857B2Targeting microRNAs for the treatment of liver cancerREGULUS THERAPEUTICS INC·Filed 2014·Granted Oct 6, 2015·4 cites·26 claims
- 1782US10301627B2Targeting microRNAs for the treatment of liver cancerREGULUS THERAPEUTICS INC·Filed 2017·Granted May 28, 2019·2 cites·24 claims
- 1881US7618947B2Modulation of HIF-1 beta expressionISIS PHARMACEUTICALS INC·Filed 2005·Granted Nov 17, 2009·4 cites·32 claims
- 1980US8410074B2Modulation of eIF4E expressionDOBIE KENNETH W·Filed 2012·Granted Apr 2, 2013·3 cites·14 claims
- 2077US9970009B2MicroRNA compounds and methods for modulating miR-21 activityREGULUS THERAPEUTICS INC·Filed 2017·Granted May 15, 2018·1 cites·20 claims
- 2176US6204055B1Antisense inhibition of Fas mediated signalingISIS PHARMACEUTICALS INC·Filed 1999·Granted Mar 20, 2001·31 cites·39 claims
- 2275US8541387B2Modulation of SMRT expressionPANDEY SANJAY K·Filed 2009·Granted Sep 24, 2013·4 cites·37 claims
- 2375US2024067963A1Compositions and methods for treatment of cardiac diseasesJAAN BIOTHERAPEUTICS LLC·Filed 2023·Application pending·0 cites
- 2470US11421232B2Compositions and methods for treatment of cardiac diseasesJAAN BIOTHERAPEUTICS LLC·Filed 2021·Granted Aug 23, 2022·0 cites·18 claims
- 2568US2010130589A1MODULATION OF eIF4E EXPRESSIONFREIER SUSAN M·Filed 2009·Application pending·0 cites
- 2667US7799764B2Modulation of HIF1-beta expressionISIS PHARMACEUTICALS INC·Filed 2009·Granted Sep 21, 2010·0 cites·31 claims
- 2767US6653133B1Antisense modulation of Fas mediated signalingISIS PHARMACEUTICALS INC·Filed 2000·Granted Nov 25, 2003·2 cites·13 claims
- 2865US8513400B2Modulation of HIF1α and HIF2α expressionWARD DONNA T·Filed 2009·Granted Aug 20, 2013·0 cites·18 claims
- 2965US2015087607A1Microrna compositions and methodsREGULUS THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 3064US2005153924A1Antisense modulation of interferon gamma receptor 2Filed 2004·Application pending·0 cites
- 3163US9845470B2Targeting microRNAS for the treatment of liver cancerREGULUS THERAPEUTICS INC·Filed 2016·Granted Dec 19, 2017·0 cites·25 claims
- 3263US2018305691A1MicroRNA Compounds and Methods for Modulating MIR-21 ActivityREGULUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3362US2007020679A1Modulation of HIF1alpha and HIF2alpha expressionISIS PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 3462US2011046206A1Double strand compositions comprising differentially modified strands for use in gene modulationISIS PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 3559US12116575B2Oligonucleotides conjugated to oleic acid and uses thereofUNIV VALENCIA·Filed 2023·Granted Oct 15, 2024·0 cites·17 claims
- 3658US2013178513A1Modulation of eif4e expressionISIS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 3758US2004033979A1Antisense modulation of Fas mediated signalingFiled 2003·Application pending·0 cites
- 3856US2003232778A1Extracellular-signal-regulated kinase-6 inhibitors for inhibiting angiogenesisFiled 2003·Application pending·0 cites
- 3955US2005261228A1Antisense modulation of interleukin 12 P35 subunit expressionBENNETT C F·Filed 2005·Application pending·0 cites
- 4054US2024307522A1Compositions and methods for the prevention and/or treatment of covid-19PROVIDENCE THERAPEUTICS HOLDINGS INC·Filed 2021·Application pending·0 cites
- 4154US2013035369A1Double strand compositions comprising differentially modified strands for use in gene modulationISIS PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 4253US2004204380A1Antisense modulation of novel anti-apoptotic bcl-2-related proteinsACKERMANN ELIZABETH J·Filed 2004·Application pending·0 cites
- 4352US2003232777A1Phosphatidylinositol-4-phosphate 5-kinase, type II beta inhibitors for inhibiting angiogenesisFiled 2003·Application pending·0 cites
- 4451US11713463B2Compositions and methods for increasing expression of SCN2ATHE FLOREY INST OF NEUROSCIENCE AND MENTAL HEALTH·Filed 2019·Granted Aug 1, 2023·0 cites·7 claims
- 4551US2002004490A1Antisense modulation of Fas mediated signalingFiled 2001·Application pending·0 cites
- 4649US2006122131A1Methods for blocking adipocyte differentiation and triglyceride accumulation with transcription factor dp-1 inhibitorsMARCUSSON ERIC G·Filed 2003·Application pending·0 cites
- 4749US2006084061A1Methods for blocking adipocyte differentiation and triglyceride accumulation with interleukin 12 p35 inhibitorsMARCUSSON ERIC G·Filed 2003·Application pending·0 cites
- 4848US2010317718A1Modulation of hif1 beta expressionISIS PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
- 4947US2005153911A1Antisense modulation of extracellular-signal-regulated kinase-6 expressionISIS PHARMACEUTICALS INC·Filed 2003·Application pending·0 cites
- 5047US2004023378A1Antisense modulation of KIAA1531 protein expressionISIS PHARMACEUTICALS INC·Filed 2002·Application pending·0 cites
Showing the top 50 of 54 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Eric G. Marcusson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →